All News PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Market Closed - Canadian Securities Exchange Other stock markets 01:29:59 01/05/2024 am IST			5-day change	1st Jan Change
0.265 ^CAD	+6.00%		+17.78%	-15.87%

23/04	PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
16/04	PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23/04	CI
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	19/04	GL
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16/04	MT
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	16/04	GL
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16/04	CI
PharmaTher Provides Update For PD-001	21/02	MT
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	21/02	GL
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	15/02	AQ
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12/02	MT
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02	GL
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02	AQ
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12/02	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27/01	CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10/01	MT
PharmaTher Provides Update for Expected FDA Approval of Ketamine	10/01	GL
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10/01	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31/23/31	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29/23/29	CI
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	27/23/27	MT
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	27/23/27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

All News

Filters